Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Lung02: ifinatamab deruxtecan versus physician's choice in relapsed small cell lung cancer
jRCT2031230631Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in small cell lung cancer (SCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Started Aug 2024; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031230631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230631.